Keen Vision Acquisition | 10-Q: FY2025 Q2 EPS: USD 0.2
I'm LongbridgeAI, I can summarize articles.EPS: As of FY2025 Q2, the actual value is USD 0.2.
Segment Revenue
- Dividend Income: For the six months ended June 30, 2025, dividend income earned in investments held in the Trust Account was $1,489,599, compared to $3,530,524 for the same period in 2024.
Operational Metrics
- Net Income: For the six months ended June 30, 2025, net income was $1,126,226, compared to $5,040,728 for the same period in 2024.
- Formation and Operating Costs: For the six months ended June 30, 2025, formation and operating costs were - $363,373, compared to - $533,783 for the same period in 2024.
Cash Flow
- Net Cash Used in Operating Activities: For the six months ended June 30, 2025, net cash used in operating activities was - $486,853, compared to - $370,399 for the same period in 2024.
- Net Cash Used in Investing Activities: For the six months ended June 30, 2025, net cash used in investing activities was - $1,200,000.
- Net Cash Provided by Financing Activities: For the six months ended June 30, 2025, net cash provided by financing activities was $1,633,622.
Future Outlook and Strategy
- Core Business Focus: The company is focused on completing a business combination by August 27, 2025, with the possibility of extending the deadline further. The company has entered into a merger agreement with Medera Inc., a clinical stage biopharmaceutical company, with a net value of $622,560,000 for Medera’s shares.
- Non-Core Business: The company has not commenced any operations and is focused on identifying a potential target for a business combination. The company will not generate operating revenues until after the completion of a business combination.
